CAPLYTA is approved for a broad range of adults with bipolar depression1
The first and only treatment for depressive episodes associated with bipolar I and bipolar II depression in adults as monotherapy and adjunctive therapy with lithium or valproate1
Clinical studies evaluating adults with a depressive episode associated with bipolar disorder (bipolar depression)1,2
| MonotherapyBipolar IBipolar II | Adjunctive (with lithium or valproate)Bipolar IBipolar II | |
|---|---|---|
| CAPLYTA | yesyes | yesyes |
| Quetiapine/Quetiapine XR | yesyes | |
| Olanzapine/Fluoxetine | yes | |
| Lurasidone | yes | yes |
| Cariprazine | yes |
| MonotherapyBP IBP II | Adjunctive*BP IBP II | |
|---|---|---|
| CAPLYTA | yesyes | yesyes |
| Quetiapine/ Quetiapine XR | yesyes | |
| Olanzapine/ Fluoxetine | yes | |
| Lurasidone | yes | yes |
| Cariprazine | yes |
*With lithium or valproate.
BP=bipolar.
There are no head-to-head clinical studies comparing the safety and efficacy of these products. This chart is descriptive of the FDA-approved indications in adults with bipolar depression and does not represent all approved indications for each product.
See proven relief for bipolar I and bipolar II depressive symptoms at the starting dose
Helpful tools & resources
References: 1. CAPLYTA prescribing information.
2. Data on File. 2021.